Ginsenoside compound K (GCK, Ginsenoside C-K, Ginsenoside K) is a deglycosylated ginsenoside metabolite with anti-inflammatory, vascular-protective and anticancer properties, targets DUSP5 to inhibit the malignant progression of glioblastoma, also inhibits PRELID3B (Kd=23 uM) to inhibit lung cancer.
Ginsenoside compound K (GCK, Ginsenoside C-K) inhibits complement C1qA/C3-CR3-mediated microglial synaptic pruning and neuronal pyroptosis.
Ginsenoside compound K (GCK, Ginsenoside C-K) inhibits and stabilizes PRELID3B in cellular thermal shift assay and bind PRELID3B with Kd of 23 uM.
Ginsenoside compound K (GCK, Ginsenoside C-K) markedly inhibited the proliferation and migration of glioblastoma cells and significantly disrupted their cell cycle.
Ginsenoside compound K (GCK, Ginsenoside C-K) suppresses glioblastoma progression by dephosphorylating p-ERK1/2 via upregulation of DUSP5 expression.
Ginsenoside compound K (GCK, Ginsenoside C-K) exerts osteoprotective effects by suppressing osteoclastogenesis and promoting preosteoclast PDGF-BB-induced angiogenesis via targeting CSF1R.
Ginsenoside compound K (GCK, Ginsenoside C-K) exhibits anti-inflammatory effects by reducing iNOS and COX-2. suppresses cancerous cell proliferation, and the safeguarding of cardiovascular, hepatic, and renal functions.